NeoGenomics, Inc., a company specializing in cancer genetics testing and information services, has recently announced the successful development of a new version of its RaDaR® technology. In addition to this exciting news, the company has also resolved litigation with Natera regarding RaDaR 1.0.
The progress of the new RaDaR technology has allowed NeoGenomics to reach a significant milestone and negotiate a resolution with Natera. While the details of the settlement remain confidential, it is important to note that it will not have a material impact on the company’s financials. The settlement does not affect NeoGenomics’ adjusted EBITDA guidance range or liquidity expectations.
To provide further updates and insights on these developments, NeoGenomics will be hosting a business update conference call and webcast on Tuesday, Sept. 24, 2024, at 8:30 a.m. Eastern Time. This call will offer investors and stakeholders the opportunity to learn more about the company’s recent advancements and future plans.
For those interested in participating in the conference call, it can be accessed via telephone by dialing (877) 545-0523 for domestic callers or (973) 528-0016 for international callers. Participants are encouraged to join the call at least five minutes before the scheduled start time and use the access code 196876.
Alternatively, the live webcast of the conference call will be available on the Investor Relations section of NeoGenomics’ website at ir.neogenomics.com. For those unable to join the live event, a replay of the webcast will be accessible shortly after the call concludes.
NeoGenomics, headquartered in Fort Myers, FL, operates CAP accredited and CLIA certified laboratories in various locations across the United States and the United Kingdom. The company’s comprehensive oncology-focused testing menus are designed to assist physicians in diagnosing and treating cancer effectively. Additionally, NeoGenomics’ Pharma Services Division works with pharmaceutical clients in clinical trials and drug development.
In conclusion, the recent advancements in RaDaR technology and the resolution of litigation with Natera mark significant milestones for NeoGenomics. The company remains committed to providing high-quality oncology testing services and driving innovation in the field of cancer genetics. Investors and stakeholders are encouraged to participate in the upcoming business update call to learn more about NeoGenomics’ progress and future plans.
